Max Robotics — Global Service Robot Directory + US Certification

About

Jorge Arredondo is a leading surgical oncologist whose research focuses on the comparative effectiveness of minimally invasive pancreatic and colorectal cancer surgeries, with a particular emphasis on robotic versus laparoscopic techniques. His most impactful work, the national prospective ROBOCOSTES trial, rigorously evaluated the cost-effectiveness of robotic distal pancreatectomy, providing crucial evidence that robotic approaches can be economically viable while maintaining clinical outcomes. This landmark study, published in 2024, has already garnered 10 citations, underscoring its immediate influence on surgical practice and healthcare policy. Arredondo also leads the PROCaRe international multicenter study, which systematically assesses patient-reported outcomes after rectal cancer treatment, prioritizing the patient experience alongside traditional oncologic metrics. His research bridges the gap between surgical innovation and real-world implementation, offering surgeons and healthcare systems data-driven guidance on adopting advanced technologies. By combining rigorous trial methodology with patient-centered endpoints, Arredondo’s work is shaping the future of minimally invasive oncologic surgery, making him a key voice in the ongoing debate over the value of robotic platforms in abdominal surgery.